Monitor for upcoming late-stage pipeline catalysts (RGX-202 for Duchenne, ABBV-RGX-314 for wet AMD/diabetic retinopathy) which are the primary value drivers. The board refresh is routine and does not change the near-term outlook.
Drugs in focus
RGNX drug pipeline →surabgene lomparvovec
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- If positive Phase 3 data in Q4 2026, regulatory filing likely 2027 with potential FDA approval 2028 for wet AMD (subretinal). Diabetic retinopathy program (NAAVIGATE) is Phase IIb/III and further out.
- Next catalyst
- None dated
What to watchWatch for topline Phase 3 data from ATMOSPHERE/ASCENT in Q4 2026, this is the single biggest binary event for RGNX. Interim ALTITUDE data at ASRS July 2026 provides a near-term sentiment check. The $100M AbbVie milestone extends cash runway into late 2027, reducing near-term dilution risk.
- ◆ NAVSUNLI 6/10 BLA resubmission pending (accelerated approval) — prior BLA reached PDUFA Feb 8, 2026 and received a Complete Response L Named in filing
- ◆ RGX-202 6/10 Phase 3 (pivotal topline complete; BLA submission planned) Named in filing
- ▼ RGX-111 2/10 Phase I/II (on FDA clinical hold since January 2026) Named in filing
- All RGNX drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 26 $9.38entry
- T+1 · 3mo ago −0.11%α −0.76% · $9.37
- T+5 · 3mo ago +2.35%α +2.47% · $9.60
- T+20 · 8w ago −22.81%α −23.04% · $7.24
- T+57 · todayOpen
- T+60 · in 2d Pending
Price Chart
How similar events traded
Executive Summary
REGENXBIO appointed Greg Ciongoli as a Class II director and accepted the resignations of Jean Bennett and Jerry Karabelas, effective August 25, 2026. The board was reduced to nine members. This is a routine board refresh with no material financial impact, though Ciongoli's capital-markets background is notable as the company approaches late-stage pipeline catalysts.
Key Facts
- Greg Ciongoli elected as Class II director effective August 25, 2026.
- Ciongoli received an initial equity award with aggregate grant date fair value of $550,000 (75% stock option, 25% RSUs).
- Option exercise price: $8.91 per share.
- Jean Bennett, M.D., Ph.D. and A.N. Jerry Karabelas, Ph.D. resigned from the board effective August 25, 2026.
- Board size reduced to nine directors.
- Ciongoli will serve on the Audit Committee and Nominating and Corporate Governance Committee.
- Ciongoli is Founder and Managing Partner of Adiumentum Capital Management.
Financial Impact
Initial equity award of $550,000 to new director; annual retainers of $45,000 (board), $10,000 (Audit Committee), $5,000 (Nominating and Corporate Governance Committee).
Risk Factors
- No material financial or operational risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-365287 |
| Document: 0001193125-26-365287-index.html | 0001193125-26-365287 |
| Document: 0001193125-26-365287.txt | 0001193125-26-365287 |
Track record
15 reports on RGNX
2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +29.65% at T+60 after the Jul 20, 2026 report. 3 of 6 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.69 Now $7.32 −4.81% settles Feb 8
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $7.38 Now $7.32 +0.81% settles Feb 3
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $7.71 Now $7.32 −5.06% settles Feb 2
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.93 Now $7.32 +5.70% settles Jan 13
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $7.26 Now $7.32 +0.83% settles Jan 8
- Aug 27, 202611w ago Insider Buy Bullish 5/10 Entry $9.66 Now $7.32 −24.22% settles Nov 23
- Aug 25, 202611w ago 8-K Neutral 3/10 Viewing Entry $9.38 Now $7.32 −21.96% settles Nov 19
- Aug 6, 202614w ago 8-K Bullish 7/10 Entry $11.28 to $7.41 Now $7.32 −35.11% ▼ −34.31% −32.88% vs SPY
- Aug 3, 202615w ago Press Release Neutral 1/10 Entry $9.96 to $6.59 Now $7.32 −26.51% ▼ −33.84% −35.62% vs SPY
- Jul 20, 202617w ago 8-K Bearish 6/10 Entry $10.32 to $7.26 Now $7.32 +29.07% ▲ +29.65% +34.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers